About this Research Topic
Cardiovascular disease (CVD) is one of the leading causes of death globally, with a major economic burden on societies. Coronary artery disease (CAD) is the most common form of CVD and is manifest as an acute coronary syndrome (ACS). It causes substantial levels of morbidity and mortality in most developed countries and greatly jeopardizes human health. Achievements in the early diagnosis, prevention, treatment, and prognosis of CAD essentially rely on the advancement of our knowledge on the complex pathophysiology CAD.
Recently, emerging evidence highlights the mechanistic role of non-coding RNA (ncRNA) in the underlying pathophysiology of CAD. Previous studies have proposed circulating non-coding RNAs as diagnostic, prognostic, as well as treatment response biomarkers in CAD and ACS. Non-coding RNAs are likely to be involved with many stages in the atherogenic process, including endothelial injury, monocyte infiltration, and lipoprotein metabolism. Beyond their regulatory role in many molecular pathways, certain ncRNAs can also control the expression of other ncRNAs, such is the case of the potential of lncRNAs and circRNAs to sequester specific miRNAs, therefore acting as miRNA sponges. A better understanding of the mechanistic role of ncRNAs in CAD and how they act in the molecular interaction could expand our knowledge of the pathophysiology of CAD. However, the impact of ncRNA on the CAD remains poorly studied. A more comprehensive exploration of ncRNA will lay the foundation for the development of ncRNA-based diagnostic and therapeutic interventions for various cardiovascular diseases especially CAD. In this Research Topic, we will be focusing on the expression and detection methods for ncRNA as well as various functions and mechanisms of ncRNA in CAD.
The aim of this Research Topic is to cover novel advances in the regulatory role and molecular interaction of ncRNA in CAD.
Areas to be covered in this Research Topic may include, but are not limited to:
1) Molecular interaction and mechanism of non-coding RNA in the occurrence and progression of CAD.
2) Novel ncRNA biomarkers for early diagnosis and prognosis for CAD.
3) Novel biological function of non-coding RNA in CAD (i.e. protein translation).
4) Non-coding RNA modifications (i.e. m6A methylation) in CAD
5) Novel therapeutic targets for precision treatment in CAD
6) Novel research tools and methods for the detection of ncRNA expression, translation, function prediction, etc.
Recently, emerging evidence highlights the mechanistic role of non-coding RNA (ncRNA) in the underlying pathophysiology of CAD. Previous studies have proposed circulating non-coding RNAs as diagnostic, prognostic, as well as treatment response biomarkers in CAD and ACS. Non-coding RNAs are likely to be involved with many stages in the atherogenic process, including endothelial injury, monocyte infiltration, and lipoprotein metabolism. Beyond their regulatory role in many molecular pathways, certain ncRNAs can also control the expression of other ncRNAs, such is the case of the potential of lncRNAs and circRNAs to sequester specific miRNAs, therefore acting as miRNA sponges. A better understanding of the mechanistic role of ncRNAs in CAD and how they act in the molecular interaction could expand our knowledge of the pathophysiology of CAD. However, the impact of ncRNA on the CAD remains poorly studied. A more comprehensive exploration of ncRNA will lay the foundation for the development of ncRNA-based diagnostic and therapeutic interventions for various cardiovascular diseases especially CAD. In this Research Topic, we will be focusing on the expression and detection methods for ncRNA as well as various functions and mechanisms of ncRNA in CAD.
The aim of this Research Topic is to cover novel advances in the regulatory role and molecular interaction of ncRNA in CAD.
Areas to be covered in this Research Topic may include, but are not limited to:
1) Molecular interaction and mechanism of non-coding RNA in the occurrence and progression of CAD.
2) Novel ncRNA biomarkers for early diagnosis and prognosis for CAD.
3) Novel biological function of non-coding RNA in CAD (i.e. protein translation).
4) Non-coding RNA modifications (i.e. m6A methylation) in CAD
5) Novel therapeutic targets for precision treatment in CAD
6) Novel research tools and methods for the detection of ncRNA expression, translation, function prediction, etc.
Keywords: Non-Coding RNA, circRNA, miRNA, lncRNA, Coronary Artery Disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
